CRISPR Gene-Edited immune cells aim to fight lung cancer – but trial never started

NCT ID NCT05566223

Terminated Disease control Sponsor: Intima Bioscience, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial planned to test a new approach for people with metastatic non-small cell lung cancer. Doctors would remove immune cells from the tumor, edit them with CRISPR to remove a gene called CISH, and then infuse them back to help fight the cancer. However, the trial was withdrawn before any patients were enrolled, so we have no data on safety or effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CISH-inactivated tumor-infiltrating lymphocytes (TILs) made with CRISPR gene editing
What this could lead to: If it works, this could point toward a new treatment option for advanced lung cancer that uses a patient's own immune cells.
What could go wrong: The trial was withdrawn before enrolling anyone, so no results exist. Gene-edited cell therapies are complex and may cause severe side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung adenocarcinoma lung large cell carcinoma non-small cell lung carcinoma squamous cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOCARCINOMA OF LUNG CARCINOMA, NON-SMALL-CELL LUNG LARGE CELL LUNG CANCER METASTATIC NON-SMALL CELL LUNG CANCER SQUAMOUS CELL LUNG CANCER STAGE IV NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Masonic Cancer Center, University of Minnesota

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.